Venture Fund Member Profile
|
 |
 |
Boston Millennia Partners has a long and successful history of venture capital investing on a national scope. Our Core Company Investment Strategy, combined with our international network of relationships and our deep industry expertise, sets us apart and enables us to add value to our portfolio companies.
We look for investment opportunities within the healthcare and life sciences industry.
We seek to partner with entrepreneurs who share our goal of building enduring, large-scale businesses that result in personal fulfillment and superior financial returns. Over the past twenty years, we have developed an investment approach that centers on active participation with our portfolio companies. Our goal is to be valuable and effective investors, while at the same time establishing productive relationships with our business partners that create long-term value. For more information, see our “What We Look For” section.
Our investing philosophy is guided by our Core Company Investment Strategy, which accelerates the growth of a company through strategic consolidation within an industry. By following a targeted merger and acquisitions plan, a core portfolio company can quickly increase its scale and broaden the scope of its product and service offerings. The result is a company that replicates a proven business model around an existing core platform to build a large, high-growth enterprise. Within the past twenty years, core companies in our portfolio have completed over 160 strategic acquisitions.
The growth and success of our portfolio companies have, in turn, allowed us to grow and expand our capital base to over $700 million. As our firm has grown, we have built a worldwide network. Investors from over a dozen countries have entrusted us to manage capital on their behalf.
 |
Bradford Callow
Principal
Boston Millennia Partners |
Brad specializes in the life sciences and healthcare sectors. He is responsible for evaluating risks and returns for current and potential portfolio investments. Prior to Boston Millennia Partners, Brad worked at Millennium Pharmaceuticals in the Investor Relations Group.
Brad received his BS in Psychology from Tufts University.
Representative Investments
 |
Arthrosurface, Inc. was organized in 2002 to develop surgical alternatives for the treatment of orthopedic joint disease. Arthrosurface's initial efforts have resulted in the development of a new method to repair isolated articular cartilage defects and damage to major joints including the knees, hips and shoulders using minimal access surgical procedures. The Company's first focus relates to the application of the technology to convex joint surfaces such as the condyles of the knee, the head of the shoulder and the ball of the hip. The Company believes that its technology can also be adapted to repair concave surfaces such as the tibial plateau, the glenoid in the shoulder and other joint surfaces. |
 |
CombinatoRx, Inc. (NASDAQ: CRXX) is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. The company applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immuno-inflammatory disease, oncology, metabolic disease, neurodegenerative disease, and infectious disease. The company is currently developing a portfolio of six product candidates targeting multiple diseases which were discovered by applying its proprietary screening technology. |
 |
MedAptus provides clinicians with a comprehensive suite of workflow and revenue enhancing solutions including: workflow management, charge capture, dictation and clinical content. The company's industry leading charge capture application is being employed by some of the country's most prestigous medical institutions to reduce physicians' administrative burdens and increase the overall quality of patient care. |
 |
Histogenics Corp expertise and focus is on repairing articular cartilage damage utilizing advancements in cell biology, tissue culture, engineering, and materials science to affect tissue repair. The Company’s technology is based on the work of Dr. Shuichi Mizuno of Brigham and Women’s Hospital, a Harvard Medical School affiliated teaching hospital, in collaboration with Takagi Industrial Co., Ltd., a Japanese firm specializing in computer-controlled machinery. |
Bradford participated in the FundingPost event: Las Vegas Angel And Early-Stage Venture Event
on Thursday, April 28, 2011 in NV, Sponsored by Technology Business Alliance of Nevada, Vegas Valley Angels, Nevadas Center for Entrepreneurship and Technology, RMSC Law
To list your Company on our website and make your profile available to Bradford and 7,500+ other VCs and Angel Investors, Click Here.
============================================
About FundingPost
For over Twelve Years FundingPost has worked with thousands
of Angel and Venture Capital Investors. We believe that it is
important to reach investors in every medium possible -
both online and offline. We have been directly responsible for
tons of success stories and Millions and Millions of dollars raised.
We look forward to introducing your company to the leading Venture and Angel Investors nationwide.
============================================
|
| Venture Fund Member Profile |
|
Bookmark to del.icio.us
Tweet this Profile
